JPMorgan Chase & Co. reaffirmed their underweight rating on shares of Haleon (LON:HLN – Get Rating) in a research report sent to investors on Wednesday, Marketbeat Ratings reports. They currently have a GBX 250 ($3.02) target price on the stock.
Several other research firms also recently weighed in on HLN. Barclays upgraded Haleon to an equal weight rating and set a GBX 348 ($4.20) price target on the stock in a research note on Tuesday, July 19th. Royal Bank of Canada reiterated a sector perform rating and set a GBX 300 ($3.62) price target on shares of Haleon in a research note on Tuesday, August 16th. Citigroup reiterated a buy rating and set a GBX 360 ($4.35) price target on shares of Haleon in a research note on Thursday, July 21st. Deutsche Bank Aktiengesellschaft reiterated a hold rating and set a GBX 300 ($3.62) price target on shares of Haleon in a research note on Wednesday. Finally, Credit Suisse Group reiterated an outperform rating and set a GBX 368 ($4.45) price target on shares of Haleon in a research note on Tuesday, July 19th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of Hold and an average price target of GBX 321 ($3.88).
Haleon Price Performance
Shares of HLN stock opened at GBX 264.90 ($3.20) on Wednesday. The company has a current ratio of 3.04, a quick ratio of 0.59 and a debt-to-equity ratio of 40.61. The stock’s fifty day simple moving average is GBX 276.35. The stock has a market cap of £24.46 billion and a P/E ratio of 1,784.00. Haleon has a 1-year low of GBX 241.17 ($2.91) and a 1-year high of GBX 337.40 ($4.08).
Insider Buying and Selling
Haleon Company Profile
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- General Mills: Superior Returns With Less Volatility
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.